New oral drug shows promise in early arthritis trial
NCT ID NCT06800157
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new oral medication called LW402 in 72 adults with moderate to severe rheumatoid arthritis who were already taking methotrexate. Participants received either LW402 or a placebo for 12 weeks to see if the drug could reduce joint swelling and pain. The goal was to find the right dose and check for safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LW402 tablets
What this could lead to
If successful, this could point toward a new oral treatment option for rheumatoid arthritis, helping to control disease activity when used with methotrexate.
What could go wrong
This is an early Phase 2a study with only 72 participants, so results may not apply to everyone. The drug may not show significant benefit over placebo, and side effects are still being evaluated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARTHRITIS, RHEUMATOID are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730, China